Trial Profile
Study to Assess Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in CMV-Seropositive Kidney Transplant Recipients Who Received Antilymphocyte Induction Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary) ; Valganciclovir
- Indications Cytomegalovirus infections
- Focus Registrational; Therapeutic Use
- Acronyms BCV CMV vGCV; SURPASS
- Sponsors Chimerix
- 20 Feb 2016 According to a Chimerix media release, status changed from active, no longer recruiting to discontinued.
- 20 Feb 2016 According to a Chimerix media release, the company has elected to close the Phase 3 SUSTAIN and SURPASS trials based on review of data from SUPPRESS trial.
- 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.